Frontier at WHX Labs Dubai 2026 advancing international partnerships

 

Frontier is attending WHX Labs Dubai this week, one of the region’s leading trade fairs for laboratory and diagnostic innovation. The visit is being led by Frontier’s Dr. Martin Burow and Marlon Luyahan.

Frontier’s participation is part-funded by Diagnostic Net BB, the diagnostics network supporting innovation across the Berlin-Brandenburg region. 

A key focus of the Dubai visit will be meeting key contacts from South East Asia – where we are already in active discussion. This is a great opportunity to progress conversations and explore potential collaborations.

Martin and Marlon will also engage with international exhibitors, researchers and industry leaders to share Frontier’s work and demonstrate the Sentinel qCTC platform.

WHX Labs Dubai brings together global stakeholders across healthcare, diagnostics and life sciences – an ideal platform to support Frontier’s continued international engagement in support of improved diagnostic solutions.

World Cancer Day & the UK’s National Cancer Plan Launch

World Cancer Day, has been in the headlines this week – and here at Frontier Diagnostics – we’re united by a shared vision; to transform the landscape of diagnostics and care for all those affected by cancer. So we welcome the launch of the UK Government’s National Cancer Plan.

 

So what is a cancer plan/strategy and why does it matter?

The International Cancer Benchmarking Partnership (ICBP) has monitored cancer data across seven countries since the 90s when the UK and Denmark were bottom of the table. Since then, Denmark’s improvement has been remarkable – thanks to successive cancer plans – each targeting their weaker areas with focused targets, transparent monitoring, absolute patient focus and significant investment.

However, unlike Denmark, the UK has had a fragmented approach with Scotland, Wales and N. Ireland having strategies in place, but England relying on the NHS Long Term Plan (2019) – which wasn’t specific to cancer and was further derailed by COVID. So the UK has been lagging behind its European neighbours  in key measures; such as the five year cancer survival rates.

So what are the headlines and will it help those with breast cancer in the UK?

  • Three out of four patients diagnosed from 2025 will be cancer-free or living well after five years, (up from 60% currently) following record investment in the NHS – which is described as the fastest improvement in cancer outcomes this century!
  • The NHS will meet all cancer waiting time standards by 2029, with hundreds of thousands more patients treated within 62 days- a target which hasn’t been met since 2015.

Faster Diagnosis

  • The plan pushes for cancer to be diagnosed earlier and more quickly, which is crucial for breast cancer outcomes because earlier-stage detection improves survival.
  • It includes measures to speed up diagnostics and meet listing time standards by 2029, so women referred with suspected breast cancer symptoms should get faster scans and results.

Improving Screening Uptake

  • While breast screening is not a new policy in the plan, the strategy’s emphasis on boosting screening and reducing inequalities supports efforts to increase breast screening participation, especially in underserved communities.
  • Earlier detection via screening increases the chances of catching breast cancer when it’s most treatable.

More Personalised Treatment

  • Wider use of genomic and molecular testing supporting more tailored treatment decisions benefiting all breast cancer sub-types

Better Access to Specialist Care

  • Emphasis on specialist cancer centres, multidisciplinary teams and modern surgical techniques to improve consistency and quality of breast cancer treatment across England.

Improved Support for Life beyond Cancer

  • Recognition of the growing number of people living with and beyond breast cancer, with a focus on recovery, quality of life and long-term support.

Better Access to Clinical Trials

  • Plans to enable patients to search and sign up for clinical trials via the NHS app – tied into national databases.

The plan is not breast cancer specific, but its focus on speed, early diagnosis, innovation and equity addresses many of the issues that matter to people with breast cancer. And from a Frontier perspective; there is a huge opportunity for us to support the UK Government’s ambitious plan over the next few years with our potential for diagnostics, personalised treatment and monitoring for recurrence support.

ABC International Consensus Conference – Programme Highlights

ABC INTERNATIONAL CONSENSUS CONFERENCE – PROGRAMME HIGHLIGHTS

From 6–8 November 2025, leading clinicians, researchers, and patient advocates gathered at the Advanced Breast Cancer (ABC) International Consensus Conference — the premier global meeting dedicated to improving care and outcomes for people living with advanced breast cancer. This conference brought together evidence-based science, clinical practice updates, and collaborative discussions to shape international treatment standards and quality-of-life care across healthcare settings worldwide.  

CONFERENCE PROGRAMME OVERVIEW 

OPENING PLENARY & GLOBAL ABC LANDSCAPE

The meeting opened with an international overview of advanced breast cancer — examining current survival trends, emerging treatments, and remaining challenges in global care. Experts highlighted progress in targeted therapies and antibody-drug conjugates, as well as the persistent need for equitable access to diagnostics and medicines.  

SCIENTIFIC SESSIONS ON TREATMENT ADVANCES

A series of scientific talks focused on the latest clinical evidence across key ABC subtypes, including;
  • Hormone receptor-positive/HER2-negative advanced breast cancer
  • HER2-positive disease treatment strategies
  • Triple-negative ABC research and novel approaches
These sessions showcased the rapid evolution of personalised medicine in metastatic care and the ongoing importance of biomarker-driven treatment decisions.

MULTIDISCIPLINARY CARE & SUPPORTIVE PRACTICE WORKSHOPS

Interactive workshops brought together clinicians, nurses, and allied health professionals to discuss:
  • Best practices in multidisciplinary team coordination
  • Managing side effects and long-term therapy support
  • Integrating psychosocial care into routine clinical practice

PATIENT VOICES & ADVOCACY PANELS

True to the ABC Global Alliance’s ethos of patient-centred care, sessions included patient advocates sharing lived experience and priorities. Topics covered communication strategies, navigating work and daily life with advanced cancer, and improving dialogue between patients and health teams.

INTERNATIONAL CONSENSUS GUIDELINES UPDATE

A core component of the programme was the consensus guideline sessions, where experts reviewed evidence and drafted updates to the ABC International Consensus Guidelines — a globally recognised set of recommendations used by clinicians to inform optimal ABC management across diverse care settings.  

IMPLEMENTATION & EQUITY IN CARE

The programme also included panels on health systems, focusing on disparities in care access, real-world implementation challenges, and strategies to translate research into practice in low- and middle-income regions.

PARTICIPATION & PRESENCE FROM OUR TEAM 

We are proud that Dr Burow, Dr Lee, and our Patient Advocate, Jane Rogerson-Gleave participated actively throughout the programme. They attended scientific sessions and guideline discussions, bringing insights from both clinical practice and patient experience. They met with presenters and conference organisers to exchange perspectives on patient priorities, communication challenges, and real-world care gaps. Jane Rogerson-Gleave’s voice reinforced the importance of living with advanced breast cancer as a partnership between patients and clinicians — not just a medical condition.
Their engagement helped ensure that patient perspectives were represented alongside scientific progress, and that conversations at the conference remain grounded in improving everyday care for people affected by advanced breast cancer.

WHY THIS MEETING MATTERS 

The ABC Consensus Conference programme reflects the state of the art in advanced breast cancer care and sets the direction for practice and policy in the years ahead. Key takeaways include:
  • Continued progress in targeted treatment and symptom management
  • A strong global focus on equity, access, and patient-centred communication
  • Updates to international guidelines that clinicians will use to guide care
This year’s programme reaffirmed that advancing outcomes requires science + systems + lived experience — and that progress grows stronger when patients and clinicians work together.